These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. PSMA PET/CT as a predictive tool for subregional importance estimates in the parotid gland. Sample C; Rahmim A; Benard F; Wu J; Clark H Biomed Phys Eng Express; 2024 Feb; 10(2):. PubMed ID: 38271732 [No Abstract] [Full Text] [Related]
12. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
13. Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine. Mohan V; Bruin NM; Tesselaar MET; de Boer JP; Vegt E; Hendrikx JJMA; Al-Mamgani A; van de Kamer JB; Sonke JJ; Vogel WV EJNMMI Res; 2021 Mar; 11(1):25. PubMed ID: 33710423 [TBL] [Abstract][Full Text] [Related]
15. Searching for Protein Off-Targets of Prostate-Specific Membrane Antigen-Targeting Radioligands in the Salivary Glands. Julian W; Sergeeva O; Cao W; Wu C; Erokwu B; Flask C; Zhang L; Wang X; Basilion J; Yang S; Lee Z Cancer Biother Radiopharm; 2024 Sep; ():. PubMed ID: 39268679 [No Abstract] [Full Text] [Related]
16. The effect of eating on the uptake of PSMA ligands in the salivary glands. Mohan V; Bruin NM; van de Kamer JB; Sonke JJ; Vogel WV EJNMMI Res; 2021 Sep; 11(1):95. PubMed ID: 34568982 [TBL] [Abstract][Full Text] [Related]
17. Preliminary results on response assessment using Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010 [TBL] [Abstract][Full Text] [Related]
19. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531 [TBL] [Abstract][Full Text] [Related]
20. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]